Journal article

Mass drug administration for the acceleration of malaria elimination in a region of Myanmar with artemisinin-resistant falciparum malaria: a cluster-randomised trial

ARD McLean, C Indrasuta, ZS Khant, AK Phyo, SM Maung, J Heaton, H Aung, Y Aung, K Soe, MMM Swe, L von Seidlein, NN Tun, KM Tun, NPJ Day, EA Ashley, T Hlaing, TT Kyaw, AM Dondorp, M Imwong, NJ White Show all

Lancet Infectious Diseases | ELSEVIER SCI LTD | Published : 2021

Abstract

Background: To contain multidrug-resistant Plasmodium falciparum, malaria elimination in the Greater Mekong subregion needs to be accelerated while current antimalarials remain effective. We evaluated the safety, effectiveness, and potential resistance selection of dihydroartemisinin–piperaquine mass drug administration (MDA) in a region with artemisinin resistance in Myanmar. Methods: We did a cluster-randomised controlled trial in rural community clusters in Kayin (Karen) state in southeast Myanmar. Malaria prevalence was assessed using ultrasensitive quantitative PCR (uPCR) in villages that were operationally suitable for MDA (villages with community willingness, no other malaria control ..

View full abstract

University of Melbourne Researchers